Effectiveness of pneumococcal polysaccharide vaccine in older adults

被引:432
作者
Jackson, LA
Neuzil, KM
Yu, OC
Benson, P
Barlow, WE
Adams, AL
Hanson, CA
Mahoney, LD
Shay, DK
Thompson, WW
机构
[1] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[6] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
关键词
D O I
10.1056/NEJMoa022678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired pneumonia. In a large population of older adults, we assessed the effectiveness of the pneumococcal vaccine. METHODS: In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years of age or older were assessed over a three-year period. The primary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review), pneumonia in patients who were not hospitalized (``outpatient pneumonia,'' determined from administrative data sources), and pneumococcal bacteremia. The association between pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-home residence or nonresidence, smoking status, medical conditions, and receipt or nonreceipt of influenza vaccine. RESULTS: During the study period, 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and 61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56; 95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospitalization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28). Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio, 1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent confidence interval, 0.99 to 1.14). CONCLUSIONS: These findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention of bacteremia, but they suggest that alternative strategies are needed to prevent nonbacteremic pneumonia, which is a more common manifestation of pneumococcal infection in elderly persons.
引用
收藏
页码:1747 / 1755
页数:9
相关论文
共 39 条
  • [1] *ADM COMM IMM PRAC, 1997, MMWR-MORBID MORTAL W, V46, P1
  • [2] COMMUNITY-ACQUIRED PNEUMONIA
    BARTLETT, JG
    MUNDY, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) : 1618 - 1624
  • [3] Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
    Black, SB
    Shinefield, HR
    Ling, S
    Hansen, J
    Fireman, B
    Spring, D
    Noyes, J
    Lewis, E
    Ray, P
    Lee, J
    Hackell, J
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) : 810 - 815
  • [4] Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
    Breiman, RF
    Keller, DW
    Phelan, MA
    Sniadack, DH
    Stephens, DS
    Rimland, D
    Farley, MM
    Schuchat, A
    Reingold, AL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) : 2633 - 2638
  • [5] The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
    Briles, DE
    Hollingshead, S
    Brooks-Walter, A
    Nabors, GS
    Ferguson, L
    Schilling, M
    Gravenstein, S
    Braun, P
    King, J
    Swift, A
    [J]. VACCINE, 2000, 18 (16) : 1707 - 1711
  • [6] Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA
    Briles, DE
    Hollingshead, SK
    King, J
    Swift, A
    Braun, PA
    Park, MK
    Ferguson, LM
    Nahm, MH
    Nabors, GS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06) : 1694 - 1701
  • [7] Centers for Disease Control and Prevention, 2000, ACT BACT COR SURV AB
  • [8] Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults:: a meta-analysis of randomized trials
    Cornu, C
    Yzèbe, D
    Léophonte, P
    Gaillat, J
    Boissel, JP
    Cucherat, M
    [J]. VACCINE, 2001, 19 (32) : 4780 - 4790
  • [9] PNEUMOCOCCAL INFECTION AND IMMUNOLOGICAL RESPONSE TO PNEUMOCOCCAL VACCINE IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - A PILOT-STUDY
    DAVIS, AL
    ARANDA, CP
    SCHIFFMAN, G
    CHRISTIANSON, LC
    [J]. CHEST, 1987, 92 (02) : 204 - 212
  • [10] *DEP HLTH HUM SERV, 1980, DHHS PUBL PHS